undamentalytics Newsletter
Sign in

Lenz Therapeutics, Inc. revenue

Lenz Therapeutics, Inc.'s revenue was $19.1m in fiscal 2025. Over the last twelve months it was $21.5m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2024Dec 20242025Dec 2025LTMJun 2026
Revenue01921
Gross profit019—
Gross margin—97.8%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Licenses $17.5M 91.7% —
Products $1.6M 8.3% —

From Lenz Therapeutics, Inc.'s 10-K filed March 24, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Lenz Therapeutics, Inc. $21.5m 329.5% —
Janux Therapeutics, Inc. $24.0m 5367.0% 45.7%
Scynexis Inc $19.2m 489.8% -47.9%
Celularity Inc $18.7m -58.1% 7.2%
Crispr Therapeutics AG $25.2m -34.3% -47.1%
Cytomx Therapeutics, Inc. $18.3m -87.0% -38.7%

Compare with peers

Head to head: JANX vs LENZLENZ vs SCYXCELU vs LENZ

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Lenz Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Lenz Therapeutics, Inc.